secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2026-07-22T12:00:09+00:00
Accession:  0001437749-26-024041
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar initiates rolling NDA submission for ALXN1840 in Wilson disease
-----------------------------------------------------------------------

- Rolling NDA submission started; first completed sections submitted to FDA.
- ALXN1840 is a first-in-class albumin tripartite complex activator for Wilson disease.
- FDA granted Fast Track, Orphan Drug, and Rare Pediatric Disease designations.
- Rare Pediatric Disease designation could yield a Priority Review Voucher upon NDA approval.
- If approved, would be first novel mechanism therapy for Wilson disease in decades.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774926024041/0001437749-26-024041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774926024041/mnpr20260721_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-024041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer